In 1987, Phase V Technologies, Inc. was founded by the University of Connecticut Research and Development Corporation and named to signify its mission to extend drug development beyond Phase 1 through Phase 4 endpoints and data collection methods.  The term “Phase V®” was trademarked as the “fifth phase” of drug development to signify technological advancements in the collection of direct-from-patient assessments and patient-centered outcomes.